858-449-1310 contact@somatek.com


A New Type of Antibody –

For a long time 5 antibody types have been known in mammals, IgG, IgM, IgA, IgE, and IgD, with IgG being the work horse in biotechnology. So it drew our attention that a group at Duke University has described a new type of anti-glycan antibody that binds to a patch of...

read more

Monoclonal for Alzheimer’s

On Monday FDA approved Biogen’s aducanumab, brand name Aduhelm, through a program called accelerated approval. Aduhelm is the first new medication for Alzheimer’s disease in nearly two decades. FDA’s decision was welcomed by patients and their families as a...

read more

RNA therapeutics

To those developing treatments for oncology, in the gene therapy space and many other fields it seemed for a long time that RNA-based therapies have many attractive properties but somehow just too many obstacles to overcome. Enter recent break-throughs in vaccine...

read more

Somatek looks back at 2020

It goes without saying, 2020 was a year with major challenges and disruptions. However, it was also a year of growth and new opportunities for the biotechnology industry and for Somatek. In the summer of 2020, Somatek moved into newly renovated laboratory facilities...

read more

HAPPY 2021

Somatek wishes all its clients, colleagues, associates and friends a very happy and healthy New Year!!

read more

Cold chain is a hot topic among investors

The Pfizer and BioNTech vaccine against COVID-19 received an emergency use authorization from the FDA last Friday, and thousands of doses are being rolled out across the country this week. But the vaccine, which must be stored at between -80 and -60 degrees Celsius, necessitates the utilization of a “cold chain” to keep it within this temperature range from the moment it leaves the manufacturing site to just before it is administered to a patient.

read more